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ABSTRACT
Background Auriculocondylar syndrome (ARCND) is a 
rare genetic disease that affects structures derived from 
the first and second pharyngeal arches, mainly resulting 
in micrognathia and auricular malformations. To date, 
pathogenic variants have been identified in three genes 
involved in the EDN1- DLX5/6 pathway (PLCB4, GNAI3 
and EDN1) and some cases remain unsolved. Here we 
studied a large unsolved four- generation family.
Methods We performed linkage analysis, resequencing 
and Capture- C to investigate the causative variant of this 
family. To test the pathogenicity of the CNV found, we 
modelled the disease in patient craniofacial progenitor 
cells, including induced pluripotent cell (iPSC)- derived 
neural crest and mesenchymal cells.
Results This study highlights a fourth locus causative 
of ARCND, represented by a tandem duplication of 
430 kb in a candidate region on chromosome 7 defined 
by linkage analysis. This duplication segregates with the 
disease in the family (LOD score=2.88) and includes 
HDAC9, which is located over 200 kb telomeric to the 
top candidate gene TWIST1. Notably, Capture- C analysis 
revealed multiple cis interactions between the TWIST1 
promoter and possible regulatory elements within the 
duplicated region. Modelling of the disease revealed an 
increased expression of HDAC9 and its neighbouring 
gene, TWIST1, in neural crest cells. We also identified 
decreased migration of iPSC- derived neural crest cells 
together with dysregulation of osteogenic differentiation 
in iPSC- affected mesenchymal stem cells.
Conclusion Our findings support the hypothesis 
that the 430 kb duplication is causative of the ARCND 
phenotype in this family and that deregulation of 
TWIST1 expression during craniofacial development can 
contribute to the phenotype.
INTRODUCTION
Auriculocondylar syndrome (ARCND) (OMIM 
#602483, #614669 and #615706), also referred 
to as ‘question mark ear syndrome’, is a rare 
Mendelian disorder with a prevalence of under 1 
in 1 000 000 (Orphanet; http://www. orpha. net/ 
consor/ cgi- bin/ index. php). ARCND is characterised 
by micrognathia, question mark ears, mandibular 
condyle hypoplasia, and other less common features 
such as microstomia, glossoptosis, postauricular 
tags and prominent cheeks.1 2 There is wide clinical 
variability, including cases with isolated ear anoma-
lies. Treatment is mainly corrective through surgical 
intervention for mandibular ramus lengthening 
using distraction osteogenesis and accompanied 
by orthodontic treatments and speech therapy.3 
Understanding the aetiology of this disorder and 
elucidating genetic causes improve counselling and 
may lead to the development of preventive or ther-
apeutic strategies, besides deepening our knowl-
edge of craniofacial development.
The main structures affected in ARCND are 
derived from the first and second pharyngeal arches 
that are colonised by neural crest cells (NCCs), 
originating from the neural plate border by epithe-
lial mesenchymal transition, and mesenchymal stem 
cells. NCCs are multipotent cells with high migra-
tory ability that can differentiate into several deriv-
atives such as cartilage, bone, peripheral neurons, 
melanocytes and glia, and they have a central role 
in craniofacial development.4 Disruption in these 
migratory, patterning or differentiation processes 
may result in congenital craniofacial malforma-
tions.5 So far, pathogenic variants in patients with 
ARCND have been found in genes of the EDN1- 
endothelin- 1 receptor type A (EDNRA) pathway, 
which are expressed by the neural crest- derived 
ectomesenchymal cells of pharyngeal arches and 
are responsible for the patterning of the mandibular 
domain in the first arch.6–8 The most commonly 
mutated gene in individuals with ARCND is 
PLCB4 (MIM 600810; 58% of patients), followed 
by GNAI3 (MIM 139370; 19% of cases) and 
EDN1 (MIM 131240 and MIM 139370; 15% of 
cases).9–12 Approximately 8% of ARCND cases 
remain unsolved.9 13
Most of the knowledge concerning ARCND 
pathogenesis comes from functional studies using 
animal models of craniofacial development, such as 
mouse and zebrafish.14 15 However, animal models 
may not completely reflect what happens in human 
development,16 and human stem cells or induced 
pluripotent cells (iPSCs) represent a complementary 
model system to study development in a human- 
specific context.17–19 iPSCs, which can differentiate 
into cell types such as NCCs and NCC- derived 
mesenchymal- like stem cells, can provide insight 
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into human craniofacial development where facial structures 
derived from the first pharyngeal arch are compromised, as 
successfully exemplified in the case of Richieri- Costa- Pereira 
syndrome (RCPS17). RCPS, caused by biallelic, hypomorphic 
alleles at the DEAD- box helicase EIF4A3,20 shares overlapping 
clinical features with ARCND particularly in mandible underde-
velopment.17 20 In this work, we studied a previously reported 
ARCND family13 and performed genetic and functional inves-
tigations using patient iPSCs that had been differentiated into 
NCC (iPSC- derived NCCs) and mesenchymal- like stem cells 
(nMSC) derivatives. Our findings suggest that duplication of 
sequences at the HDAC9 locus can lead to the development 
of ARCND, possibly by disruption of regulatory elements that 
control expression of the neighbouring TWIST1 gene.
MATERIALS AND METHODS
Patients and DNA samples
The Brazilian family (referred to as F1; online supplemental 
table 1) is a non- consanguineous family with 11 members 
showing the typical characteristics of ARCND. Of those docu-
mented, the majority presented with question mark ears (8 of 
10), microstomia (8 of 10) and micrognathia (6 of 10), with 
considerable intrafamilial variability observed.13 Genomic DNA 
was extracted from peripheral blood lymphocytes according to 
Miller et al.21
Sanger sequencing
Primers and conditions used in PCR amplification prior to Sanger 
sequencing were as described in Romanelli Tavares et al.22 The 
data were analysed using Sequencher V.5.1 software (http:// 
genecodes. com/). Variants present in the 1000 Genomes Data-
base, dbSNP150 (through University of California, Santa Cruz 
Genome Browser, UCSC; https:// genome. ucsc. edu/), Genome 
Aggregation Database (https:// gnomad. broadinstitute. org/) or in 
the Online Archive of Brazilian Mutations (http:// abraom. ib. usp. 
br/) were considered unlikely to be pathogenic.
Linkage analysis
Nine affected individuals (II- 4, II- 6, II- 8, III- 5, III- 10, III- 13, III- 
14, IV- 3 and IV- 6) and three unaffected individuals (III- 6, III- 11 
and IV- 4) were genotyped using the GeneChip Human Mapping 
50K Array Xba 240 (Affymetrix), according to the manufactur-
er’s protocol. The genotype data were analysed using Affymetrix 
Genotyping Console. The overall quality of the samples was esti-
mated through quality control (QC) algorithm (dynamic model 
algorithm with QC call rate) using a threshold of 90%.
Linkage analysis was performed with the easyLINKAGE- Plus 
V.5.08 package.23 Mendelian inconsistencies were removed using 
PedCheck V.1.024 and the non- Mendelian inconsistencies with 
Merlin V.1.0.1 software.25 The logarithmic odds (LOD) score 
was obtained using the parametric multipoint test with GeneHu-
nter V.2.1r5.23 26 Analysis parameters were defined as autosomal 
dominant, estimated penetrance K=0.9, disease allele frequency 
estimated at 0.0001 and marker spacing at 0.0010 cM, and map 
distances were acquired from AFFY 100K deCODE Human 
GRCh37/hg19, and SNPs with a call rate less than 90% were 
removed.
The candidate region was confirmed by amplification of 
microsatellite markers from the ABI PRISM Linkage Mapping 
Set V.2.0 (Perkin- Elmer, Applied Biosystems, Foster City, Cali-
fornia), read in a MegaBACE 1000 automatic sequencer (Amer-
sham, GE Healthcare, Little Chalfont, UK) according to the 
manufacturer’s protocol and analysed with MegaBACE Genetic 
Profiler software (Amersham, GE Healthcare).
Endeavour gene prioritisation was applied to the candidate 
Chr7 region (https:// endeavour. esat. kuleuven. be/)27 to generate 
a candidate gene list. Training gene lists (reference genes) were 
compiled according to the following criteria: (a) genes with a 
central role in the formation of the structures affected in patients 
with ARCND (eg, ears, mandible and mandibular condyle); or 
(b) genes related to the embryonic developmental processes 
involved in the formation of some of the structures affected in 
patients with ARCND (eg, neural crest and formation of the first 
and second pharyngeal arches) (online supplemental table 2).
Whole exome sequencing
Whole exome libraries were generated using either the Agilent 
SureSelect Human All Exon 50 Mb Kit (patients IV- 3 and IV- 6; 
performed at the Center for Human and Clinical Genetics, 
Leiden University Medical Center, The Netherlands) or the Illu-
mina TruSeq Kit (patients III- 10 and III- 13; performed at Luiz 
de Queiroz College of Agriculture, São Paulo, Piracicaba, Brazil). 
Whole exome sequencing (WES) was carried out on Illumina 
HiSeq 2000 (2 x 100 bp paired- end run). Sequences were aligned 
to the human reference GRCh37 (hg19) using the Burrows- 
Wheeler Aligner (BWA).28 Processing and variant calling were 
performed along with batch samples using the Unified Geno-
typer tool (Genome Analysis Toolkit, GATK) (http://www. broa-
dinstitute. org/ gatk/),29 using default parameters, with exception 
to the following changes: minIndelCnt 3; minIndelFrac 0.020; 
contamination 0.02; metrics snps.metrics; stand_call_conf 30.0; 
stand_emit_conf 10.0; min_base_quality_score 12; dcov 300; 
baq CALCULATE_AS_NECESSARY. Annotation was done with 
Annovar (http:// annovar. openbioinformatics. org/).30 Variants 
were selected if they had been approved by the filter quality 
(PASS), frequency ≤0.01 in 1000 Genomes Database (https://
www. internationalgenome. org/) and Exome Variant Server 
(ESP6500; https:// evs. gs. washington. edu/ EVS/), heterozygous 
genotype in all four affected individuals sequenced, and with 
allele count ≤4 in the local sequenced cohort of patients without 
ARCND (total allele number=132).
Targeted sequencing
Targeted sequencing at the HDAC9/TWIST1 locus was performed 
using a resequencing capture panel designed to the TWIST1 gene 
and flanking regions (2.4 Mb with boundaries selected according 
to human to mouse synteny; chr7:17,346,143–19,695,462, 
GRCh38).31 Genomic DNA from family members (three 
affected and one unaffected family members: IV- 3, IV- 6, III- 5, 
II- 7) was fragmented by sonication, ligated to indexed Illumina 
sequencing adapters and amplified. Purified libraries were mixed 
with the biotinylated probe mixture (SeqCap EZ Choice Library 
System, Roche Nimblegen) and enriched DNA for the targeted 
regions sequenced on an Illumina HiSeq 2500. Sequencing 
adapter sequences and low- quality bases were removed using 
Trimmomatic (V.0.32; parameter SLIDINGWINDOW: 4:2032) 
and the trimmed read pairs were then aligned to human reference 
genome hg19 using BWA (V.0.7.12) with default parameters.28 
The aligned reads were analysed using amplimap (V.0.2.9)33 
and coverage calculated using BEDtools V.0.25.0.34 Variants 
were called separately in each sample using Platypus (V.0.8.1)35 
and then concatenated, merged and normalised using BCFtools 
(V.1.5; https:// github. com/ samtools/ bcftools) and annotated 
with Annovar.30
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For the breakpoint isolation, we examined the resequencing 
data at the duplication junctions and designed the following 
primers to amplify the breakpoint: F- 5′- CCCA TGCC TCAT 
TCTT TCTTTG- 3′ and R- 5′- TGGCAGGCTTTAGTGTTCTT- 3′.
Capture-C
To identify the chromatin regions that the TWIST1 promoter 
interacts with, we used a Capture- C approach.36 For the chro-
matin template we prepared human mesenchymal cells from 
human embryonic calvaria (three different samples at 12–14 
postconception weeks, provided by the Human Developmental 
Biology Resource, UK). We removed the skin and dura mater and 
then dissected a bony strip (approximately 0.5 mm wide) that 
included the frontal bone, coronal suture and parietal bone and 
placed this in a gelatinised culture dish containing the following 
selective medium: BHK- 21 Glasgow MEM (Gibco 21710- 
025)—to this 500 mL we added glutamine (Gibco 25030- 024), 
2 mM sodium pyruvate (Gibco 11360- 039), 100 U/mL peni-
cillin/streptomycin, non- essential amino acids (Gibco 11140- 
035), 10% Fetal Bovine Serum (FBS) (Gibco 10270), 0.1 mM 
β-mercaptoethanol and Lif (inhouse prepared Lif- containing 
medium from modified Chinese Hamster Ovary (CHO) cells). 
Cells were allowed to grow out of the bone for 3–5 days and then 
collected (discarding the bony strips) and cultured again using 
the same media. Cells were passaged at least twice more before 
collection for 3C library preparation. Cells (10–15 million) 
were fixed in formaldehyde and then lysed prior to digestion of 
the cross- linked DNA template with DpnII and DNA ligation. 
Following DNA purification, the 3C library was sonicated and 
used to prepare a sequencing library which was then mixed with 
biotinylated oligonucleotides to enrich for fragments containing 
the TWIST1 promoter. Two successive rounds of capture were 
performed. Biotinylated oligonucleotides were designed using 
an online tool (http:// apps. molbiol. ox. ac. uk/ CaptureC/ cgibin/ 
CapSequm. cgi) to each side of a DpnII fragment that over-
lapped with the TWIST1 promoter: TWIST1pro1:  ATCC AGTG 
GACA ATTA GGCT TCGT GAGC CCCA ATTC CAAA TGCT 
TGGA TACG CTAA CATT TTAA GCAT TTCT GTCT GTAA GTTA 
AAAC GAAG AGCC CCAA AGAG GGTG TTAA TGTAGATC and 
TWIST1pro2:  GATC TTCC GCAG CGCG GCGA ACGC CTCG 
TTCA GCGA CTGG GTGC GCTG GCGC TCCC GCAC GTTG 
GCCA TGAC CCGC TGCG TCTG CAGC TCCT CGTA AGAC 
TGCG GACT CCCG CCGCCGCT. Captured fragments were 
sequenced on an Illumina MiSeq (2 x 150 bp paired- end run; 
MRC Weatherall Institute of Molecular Medicine (WIMM), 
Oxford).
Generation of iPSC, NCC and MSC
Three ARCND samples and three control samples were used for 
generation of iPSCs. One of the control iPSCs used in this study 
(F7405- 1) had been generated with retroviral transduction and was 
described and characterised elsewhere.37 The other cells were estab-
lished from erythroblast cultures derived from peripheral blood 
collection (from three affected individuals: II- 4, II- 8 and III- 5; 
and two non- related controls: F8799 and F9048), reprogrammed 
as described in Okita et al38 in an Amaxa Nucleofector II (T- 016 
program for erythroblasts) with either NHDF (Normal Human 
Dermal Fibroblasts) or CD34+ (erythroblasts) nucleofector kits 
(Lonza), according to the manufacturer’s recommendations. After 
nucleoporation, iPSCs were obtained exactly as described in Miller 
et al.17 Derivation of NCC from iPSC and Mesenchymal Stem Cells 
(MSC) differentiation from NCC were also performed as previously 
published.39 Characterisation of iPSC, NCC and MSC is described 
in the online supplemental material along with the antibodies used 
(online supplemental table 3). To assess EDN1/EDNRA pathway- 
related gene expression, NCCs were treated with EDN1 100 nM 
for 24 hours.
MSC osteogenic differentiation
Cells were seeded in 12- well plates (Corning) (104 cells/cm2) in 
triplicate. After 3 days, the medium was replaced with an osteo-
genic induction medium (StemPro Osteogenesis Kit, Life Tech-
nologies); in parallel, negative controls were cultivated in MSC 
medium. Differentiation and the MSC media were changed 
every 2–3 days. After 9 days, alkaline phosphatase (ALP) activity 
was quantified through incubation with phosphatase substrate 
(Sigma- Aldrich), and the resulting p- nitrophenol was quanti-
fied colourimetrically using Multiskan EX ELISA Plate Reader 
(Thermo Scientific) at 405 nm. Absorbance data were normalised 
by subtracting from undifferentiated, negative controls.
Wound healing assay
NCCs were seeded at 5×105 cells/cm2 into non- coated 
24- well plates (Corning) in NCC medium. When cells reached 
90%–100% confluence, the monolayer was scratched in a 
straight line with a p200 pipette tip. The culture medium was 
then replaced and cell migration images were acquired at 0 hour 
and 24 hours. All samples were assessed simultaneously in two 
independent experiments. The percentage of the wound covered 
by migrating cells after 24 hours was quantified in ARCND and 
control NCCs using ImageJ.
Cell cycle assay
To determine the percentage of cells in G0/G1, S and G2/M phases 
based on DNA content, a cell cycle assay was performed using 
the Guava Cell Cycle Reagent (Millipore). Cells were seeded at a 
density of 0.2×105 cells/cm2. When the cell culture reached 50% 
confluence, cells were cultured in NCC medium without basic- 
fibroblast growth factor (bFGF) for 24 hours. Complete NCC 
medium was added afterwards and the next day cells were detached 
using Accutase to obtain a single- cell suspension and neutralised 
with Dulbecco's Modified Eagle Medium (DMEM). Suspended 
cells were collected in a tube and centrifuged at 450 g for 5 min. 
The supernatant was removed and ice- cold 70% ethanol was added 
gently to the cell pellet and stored in −20°C for at least 3 hours. 
Fixed cells were washed in phosphate- buffered saline (PBS), resus-
pended with Guava Cell Cycle Reagent and incubated for 30 min 
in the dark. Cells were analysed with the Guava EasyCyte Flow 
Cytometer (Millipore) according to the manufacturer’s instructions.
Real-time QPCR
Total RNA was extracted from cells with the NucleoSpin RNA 
II Extraction Kit (Macherey- Nagel) following the manufactur-
er’s recommendations. Total RNA was converted into cDNA 
using SuperScript IV (Life Technologies) and oligo- dT primers. 
Real- time QPCR reactions were performed with 2X Fast SYBR 
Green PCR Master Mix (Life Technologies) and 50–400 nM of 
each primer. Fluorescence was detected using the QuantStudio 
5 System (Life Technologies) under a standard temperature 
protocol. Primer pairs were either designed with Primer- BLAST 
or retrieved from PrimerBank and supplied by Exxtend (online 
supplemental table 4). geNorm (https:// genorm. cmgg. be/) was 
used to determine the normalisation factor (using gene expres-
sion of TATA- box binding protein (TBP), hydroxymethylbilane 
synthase (HMBS) or glyceraldehyde- 3- phosphate dehydroge-
nase (GAPDH)) and calculate normalisation factors (E−ΔC) for 
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each sample. The final relative expression values were deter-
mined based on the Pfaffl40 method.
Statistical analysis
All experiments were performed in triplicate, unless stated other-
wise. Statistical comparisons were performed using GraphPad 
Prism V.5 software. Unpaired Student’s t- test and two- way anal-
ysis of variance (ANOVA) values were represented as mean±SE. 
The level of statistical significance was set at p<0.05.
RESULTS
Evidence of a fourth locus for ARCND
Sanger sequencing of PLCB4, GNAI3 and EDN1 did not reveal 
any pathogenic variants in the coding regions, 5′ UTRs (untrans-
lated regions) or splice sites of these genes, suggesting that a 
different locus might underlie the ARCND in the family. Next, 
we carried out a linkage analysis that revealed three regions 
with positive LOD scores on chromosomes 7, 14 and 18 (online 
supplemental figure 1). The highest LOD score (2.88), which 
is close to the threshold value of ≥3.0 for significance41 and 
the maximum theoretical LOD score for this family (2.93), 
was observed in a region of about 17.6 Mb on chromosome 7 
(chr7:14395902–32017194 (hg38); table 1). Genotyping of 
microsatellite markers narrowed the chromosome 7 linkage 
region to chr7:14395902–28158440 (hg38) (online supple-
mental figure 2).
We performed WES on four affected individuals. After filtering 
(as described in the methods), only one variant from the candi-
date regions on chromosomes 7, 14 and 18 remained, a synon-
ymous change located in TRIL (NM_014817.3:c.345G>A; 
p.(=)), classified as a variant of uncertain significance (BP4, PM2 
and PP4 according to the American College of Medical Genetics 
and Genomics guidelines42). Sanger sequencing of additional 
family members (nine affected and five non- affected individuals) 
showed that the variant did not segregate with the disease and 
therefore it was not considered further. Variants in candidate 
genes within the endothelin pathway (EDN1, EDNRA, DLX5, 
DLX6, FURIN and ECE1) were also investigated with WES in the 
same manner, but no obvious pathogenic variants were detected. 
We then took a gene prioritisation approach, and TWIST1 was 
the top- ranked gene in this analysis using two training lists, with 
a p value equal to 0.00053 and 0.00027 (using training lists ‘a’ 
and ‘b’, respectively; online supplemental table 5). TWIST1, a 
basic transcription factor of the helix- loop- helix (bHLH) family, 
is expressed in cranial mesoderm and neural crest- derived 
mesenchyme, which are tissues involved in craniofacial devel-
opment.43 44 Its role in mandibular condyle and mandible forma-
tion has also been demonstrated.45 46 These observations led us 
to further investigate the genomic region surrounding TWIST1.
Targeted resequencing of a 2.4 Mb region around TWIST131 
revealed no potential pathogenic variants in TWIST1, but did 
detect a tandem duplication within HDAC9 that was only present 
within the three affected family members tested (figure 1A and 
online supplemental figure 3). We designed primers to the 
sequences either side of the duplication and characterised the 
duplication breakpoint (figure 1B,C). The duplication spanned 
430 302 bp (NC_000007.14:g.18437239_18867540dup) telo-
meric to TWIST1, covering most of the HDAC9 gene. Multiple 
transcript isoforms of HDAC9 are duplicated in their entirety 
(including transcript isoforms 3, 8, 9, 10 and 11); however, 
full- length catalytically active transcript isoforms47 (transcript 
isoforms 1, 5, 6 and 7) extend beyond the breakpoint and 
therefore are likely to be disrupted by this duplication. Break-
point amplification and Sanger sequencing within the family 
demonstrated segregation of the duplication with the phenotype 
(figure 1B). All unaffected individuals were negative, suggesting 
full penetrance in this family (online supplemental figure 4).
Analysis of CNVs in DECIPHER (https:// decipher. sanger. ac. 
uk/)48 revealed 19 patients with copy- number gains in the region. 
With the exception of a single small duplication (patient identi-
fication 276644), all the CNVs that overlap the one described 
here are much larger and encompass multiple genes. Never-
theless, 7 out of 19 have descriptions that include ear malfor-
mation among other features (patient identification: 393911, 
393942, 395511, 396512, 280316, 396373 and 394346) 
include enhancer eTW6 (Hs2307) that regulates the expression 
of Twist149 and other two regulatory elements (eTW7 (Hs2306) 
and (eTW5) Hs644; VISTA Enhancer Browser). Similarly, 7 out 
of 19 DECIPHER patients presented with micrognathia (patient 
identification: 393911, 393942, 395511, 280316, 2363, 
396373 and 394346); these duplications also include eTW6, 
except for individual 2363. Interestingly, one of the DECIPHER 
duplications (276644; 179 kb) is enclosed entirely within the 
ARCND duplicated region; however, this patient does not have 
ARCND clinical features (2021, Olivier Faivre, L., personal 
communication). We note that the non- overlapping sequence 
between patient 276644 and the ARCND duplication includes 
the aforementioned regulatory TWIST1 elements (online supple-
mental figure 5 and table 6).
To explore how the duplication identified above, which is 
over 200 kb telomeric to the candidate gene TWIST1, could 
be pathogenic, we carried out a Capture- C analysis50 using the 
TWIST1 promoter as the viewpoint. This demonstrated that 
there were multiple contacts between TWIST1 and regions to 
either side. The highest frequency of interactions was telomeric 
of TWIST1, particularly within the HDAC9 gene and the region 
spanned by the duplication (figure 1A). This implies that this 
region contains regulatory elements involved in the control of 
TWIST1 expression, providing a possible pathogenic mechanism 
for the duplication.
Table 1 Regions with positive logarithmic odds (LOD) scores obtained by linkage analysis




From To Region size 
(Mb)
Number of genes (NCBI 
RefSeq curated)rsID Physical position hg38 (bp) rsID Physical position hg38 (bp)
Chr7 2.88 rs1036140 14 395 902 rs28190 32 017 194 17.6 146
Chr14 2.41 rs10484206 49 103 955 rs10498419 49 978 179 0.87 14
Chr18 1.67 rs1398193 48 460 768 rs768360 50 237 703 1.8 20
The maximum theoretical LOD score for this family was equal to 2.93.
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Analysis of the duplication in iPSC and craniofacial progenitor 
cells
To further investigate the pathogenicity of the duplication, we 
used an in vitro approach to model the disease, generating iPSC 
from affected and unaffected individuals in the family. The 
experimental design was based on recapitulating different stages 
of early embryonic development that are relevant to the ARCND 
phenotype, most particularly iNCC (iPSC- derived NCCs) and 
nMSC (iNCC- derived mesenchymal- cell like). All cell types 
were fully characterised and showed cellular specific expression 
of relevant markers and typical cell morphology (online supple-
mental figures 6–8).
Expression analysis of HDAC9, TWIST1 and ARCND-related 
markers
Previous analysis of HDAC9 has shown that it contains regula-
tory elements important for TWIST1 expression.49 51 Together 
with our prioritisation and Capture- C analysis, this prompted 
us to investigate the expression of both of these genes in iPSC 
and derived cell types. TWIST1 and HDAC9 mRNA in iPSC did 
not show any difference between patients and controls (data not 
shown). However, an increase in HDAC9 (3.15- fold, unpaired 
t- test p=0.009) and TWIST1 (2.03- fold, unpaired t- test p=0.03) 
mRNA was observed in the ARCND- iNCC (figure 2A,B) 
compared with controls (unpaired t- test).
In order to evaluate if there is deregulation of the EDN1 
pathway in the ARCND cells, we investigated the expression of 
the key downstream target of this pathway, DLX5,15 52 as well 
as other genes shown to be activated, BARX1, NKX3.2, GSC, 
DLX3 and HAND2.53 54 Expression of BARX1, NKX3.2 and GSC 
was not significantly different between controls and ARCND 
iNCCs (two- way ANOVA, p>0.05; online supplemental figure 
9), while HAND2, DLX3 and DLX5 mRNA levels were too low 
to be measured (data not shown).
Analysis of ARCND iNCC and nMSC function
To screen for cellular phenotypes, we assessed cell cycle and 
migration of ARCND iNCC compared with controls, as alter-
ations in these cellular functions are considered to be underlying 
mechanisms in several NCC- related diseases.17 55 56 Although 
no significant difference in cell cycle distribution was detected 
between patient and control cells, a significant decrease in 
migratory capacity of ARCND iNCCs was observed compared 
with controls (4.3- fold decrease, Student’s t- test, p=0.0009) 
(figure 2C–E).
Marked mandibular hypoplasia is often seen in patients with 
ARCND, which could be caused by dysregulation of osteo-
genic differentiation. Therefore, we investigated this process in 
nMSCs. Our data showed that during osteogenic differentiation, 
ALP enzymatic activity was significantly diminished in ARCND- 
nMSCs after 9 days of osteoinduction (decrease of 20.3- fold, 
paired t- test p=0.029; figure 3A,B). In addition, alizarin red 
staining revealed a subtle decrease in matrix mineralisation in 
ARCND- nMSCs in comparison with controls (t- test p<0.05; 
figure 3C). Next, we assessed the expression of key osteogen-
esis genes (figure 3D–I). ALP showed a statistically significant 
downregulation (p=0.035), whereas MSX2 expression was 
higher in ARCND- nMSC compared with the controls, although 
not reaching statistical significance. No significant difference 
Figure 1 The ARCND 430 kb duplication. (A) Top: ideogram of the chromosome 7 linkage region (red square) indicating the duplicated region (green 
square). Middle: the HDAC9/TWIST1 locus and duplicated region (chr7:18 437 238–18 867 540, hg38; blue bar), with Capture- C data above showing cis 
interactions (the green peaks indicating the frequency of contacts) between the TWIST1 promoter and possible regulatory elements. The overall domain of 
interactions is indicated by the black arrowheads; the highest frequency of contacts is within HDAC9. The positions of Twist1 enhancers eTw5- 751 are shown 
in relation to the duplication. Bottom: University of California, Santa Cruz (UCSC) Genome Browser tracks for enrichment levels of the H3K27Ac histone 
mark across the selected region and conservation (https://genome.ucsc.edu/index.html). (B) Left: pedigree of the ARCND family with the proband indicated. 
Right: schematic figure of the duplication (NC_000007.14:g.18437239_18867540dup) and breakpoint PCR. The arrow indicates the duplication breakpoint 
product; affected individuals are marked with an asterisk. (C) Electropherogram of representative Sanger sequencing from an individual with ARCND 
showing the breakpoint nucleotide sequence. All figures are according to GRCh38 coordinates. ARCND, auriculocondylar syndrome.
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was seen in the expression of RUNX2, TWIST1, BGLAP and 
COL1A1. Together, these results indicate a delay or impairment 
of osteogenic differentiation.
DISCUSSION
In this work, we used linkage and resequencing analysis to reveal 
a new ARCND locus on chromosome 7. We identified a novel 
430 kb CNV that duplicated sequences beginning ~280 kb telo-
meric of TWIST1, the gene prioritised as the best candidate for 
the phenotype in the linkage region. The CNV, which segregated 
with the disease in a four- generation large Brazilian family, dupli-
cated possible regulatory element sequences within HDAC9, 
which we demonstrated, through a chromosome conformation 
capture assay, make contact with the TWIST1 promoter. This 
aligns with previous studies of this region that show that mouse 
Twist1 regulatory regions can be found within both introns and 
exons of the Hdac9 gene.49 51 57 Notably, a 23 kb deletion that 
included three of these regulatory element sequences, which may 
also be bound by craniofacial transcription factors Lmx1b and 
Tfap2, was associated with a reduction in Twist1 expression.51 
Figure 2 RT- QPCR assessment of (A) HDAC9 and (B) Twist1 showing upregulated expression in ARCND- derived NCC. Both genes showed statistically 
significant differences among controls and ARCND. **Two- tailed p=0.0094; *one- tailed p=0.0250, unpaired Student’s t- test. (C–E) Evaluation of cell cycle 
and cell migration in ARCND NCC. (C) Cell cycle assay, not statistically significant. (D) Bar graph depicting the rate of cell migration (cell- covered area, 
%) after 24 hours; data shown are representative of two independent assays and three independent measurements in each. ***Two- tailed, p=0.0009, 
Student’s t- test. (E) Representative phase- contrast micrographs acquired immediately after wounding at 0 and 24 hours. All values represent mean±SEM. 
ARCND, auriculocondylar syndrome; AU, arbitrary unit; NCC, neural crest cells.
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Furthermore, rearrangements that leave the gene intact but 
remove regions telomeric of TWIST1 lead to Saethre- Chotzen 
syndrome (SCS),58–61 which is caused by TWIST1 haploinsuffi-
ciency. SCS is characterised by craniosynostosis of the coronal 
sutures, which is not found in ARCND. Overall, these findings 
underline the importance of this region for TWIST1 regula-
tion and suggest that duplication of these and other regulatory 
elements could be associated with altered TWIST1 expression 
during development. Importantly, transgenic enhancer assays 
have demonstrated in both mouse and zebrafish that some of 
these regulatory elements can drive Twist1 pharyngeal expres-
sion. For example, the enhancer known as eTw651 or Hs2307 
(Vista Enhancer Browser62) that overlaps with Hdac9 exon 19 
drives the expression of Twist1 in mouse E11.5 pharyngeal 
arches,49 51 providing a mechanism whereby rearrangements at 
this genomic locus could lead to the pharyngeal arch- related 
developmental abnormalities found in ARCND. Further support 
for a link between increased TWIST1 expression and the devel-
opmental anomalies found in our ARCND family comes from 
overlap with the clinical features described in cases with three 
copies of the 7p chromosomal region. For example, micrognathia 
or small mandibles have been found in patients with partial 
trisomy 7p.63–66 We note, however, that our patients did not 
have large, open fontanelles, the hallmark feature of trisomy 7p 
which has been linked to triple dosage of TWIST1,67 which may 
reflect having three copies of regulatory elements rather than 
Figure 3 Evaluation of osteogenic potential in ARCND- mesenchymal stem cells (MSC). (A) Quantification of ALP enzymatic activity after 9 days and (B) 
alizarin red staining after 21 days of osteoinduction in ARCND- MSC in comparison with controls. Measurements from differentiated cells were normalised to 
paired, undifferentiated negative staining controls. (A and B) Student’s t- test, ALP activity two- sided and alizarin red one- sided (*p<0.05). (C) Representative 
alizarin red staining micrographs showing matrix mineralisation (in dark brown) of ARCND- MSC samples versus one representative control (osteogenic 
differentiation for 9 days); micrographs are shown paired to respective negative controls (undifferentiated cells). (D–I) Transcriptional profiles of TWIST1 and 
osteogenic differentiation markers during the initial 6 days of osteoinduction. ALP was statistically significant (*p<0.05). MSX2, RUNX2, COL1A1 and BGLAP 
did not show statistically significant differences (ns). All values represent mean±SEM. (D–I) Two- way ANOVA with Bonferroni post- tests. (C) Scale bars: 
1000 µm. ALP, alkaline phosphatase; ANOVA, analysis of variance; ARCND, auriculocondylar syndrome; AU, arbitrary units; MSC, mesenchymal stem cells 
(undifferentiated cells); OST, osteogenic differentiation.
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three copies of the gene itself. Similarly, a significant number of 
DECIPHER duplications (~40%) at this locus were also asso-
ciated with ARCND overlapping features, despite the variable 
phenotype and incomplete penetrance of ARCND.9 10 13 68 Inter-
estingly, one of the duplications (276644) was entirely contained 
within the ARCND duplication, but this CNV did not span the 
known Twist1 regulatory element51 and the case was not asso-
ciated with any features of ARCND. Altogether, these observa-
tions reinforce that the 430 kb HDAC9 duplication is pathogenic 
and that altered expression of TWIST1 might contribute to the 
ARCND phenotype.
To investigate the pathogenicity of the CNV, we used an iPSC- 
based approach to screen for molecular and cellular alterations 
associated with ARCND in the family. As the affected craniofa-
cial structures in ARCND arise from the neural crest, we gener-
ated and analysed NCC derived from patient and control iPSCs 
and found upregulation of both HDAC9 and TWIST1. Only the 
shorter, catalytically inactive forms of HDAC947 could be tran-
scribed from within the duplication to account for the upreg-
ulation of this gene, while the larger transcripts (the catalytic 
domain is encoded by multiple exons at the 3′ end of the gene) 
are predicted to be disrupted. HDAC9, a class II histone deacety-
lase enzyme, usually associated with transcriptional repression,69 
has been linked to many types of cancer such as glioblastoma, 
breast cancer and oral squamous cell carcinoma, and chronic 
disorders such as diabetes and osteoporosis.70–72 There is no 
evidence of a role of HDAC9 in craniofacial development and 
it is not expressed in mouse E11.5 pharyngeal arch,49 although 
a role in bone development is possible as Hdac9 expression has 
been shown to increase osteoclastogenesis and regulate osteogen-
esis,73 74 and a contribution to the development of the ARCND 
phenotype cannot be excluded. In contrast, the relevance of 
TWIST1 in craniofacial development has been highlighted by the 
human conditions SCS75 76 and Sweeney- Cox syndrome,77 which 
are caused by pathogenic variants in this gene, as well as by 
studies of Twist1 mouse models.43 46 Moreover, Twist1 directly 
inhibits Runx2,78 79 the master regulator of osteogenic differenti-
ation, as well as downstream targets of Runx2 like bone sialopro-
tein.80 Its overexpression leads to reduced ossification78 81 and 
conditional inactivation of Twist1 has demonstrated an essen-
tial role in the survival of NCC in mandibular development, as 
well as in ossification of the mandible leading to mandibular 
hypoplasia, condylar process loss and altered middle ear.43 46 Of 
note, a comparable mandibular phenotype is also observed in a 
mouse model deleted for the enhancer that regulates pharyngeal 
arch expression of Hand2,82 a bHLH transcription factor that 
dimerises with Twist1 in mandible development.83 84 Together, 
this supports the contention that deregulation of TWIST1, as 
we have shown in iNCCs, could contribute to the ARCND 
phenotype.
As Twist1 knockout in different mutant animal models leads 
to defective NCC migration,85 86 we performed in vitro scratch 
assays on iNCC derived from affected family members and 
controls and found significant reduction in ARCND- iNCCs. 
Reduced migration in early NCC stages has been found in RCPS, 
a craniofacial disorder also characterised by underdevelopment 
of mandibles and shown to be related to altered neural crest 
functions.17 The reduced migration found in ARCND- iNCC is in 
contrast to previous data showing that reduced migration is asso-
ciated with loss of Twist1 in mice,85 86 as opposed to increased 
expression, as found here. An explanation for this might be 
that the iNCCs modelled in this study are in an earlier develop-
mental stage and/or lack factors necessary to activate endothelin 
signalling, which are secreted by tissues within the pharyngeal 
arches in vivo.87 This may account for the low DLX5/6 expres-
sion observed in our experiments. Although the iNCC deriva-
tion protocol used here is biased towards the cranial neural crest 
lineage,88 expression profiling assays will be necessary to further 
clarify the positional identity and developmental stage of iNCCs. 
Our observations suggest that upregulation or downregulation 
of TWIST1 levels can lead to reduced migration depending on 
the developmental stage. The migration defect could potentially 
explain ARCND features through a reduction in NCC reaching 
the first and second pharyngeal arches, resulting in malformed 
derivatives such as mandible and external ear, a mechanism that 
also seems to be involved in RCPS.17 In regard to HDAC9, even 
though its overexpression has been associated with increased 
proliferation and migration in cancer cells, to date this gene has 
not been associated with neural crest proliferation/migration or 
specification of craniofacial elements.
Furthermore, our osteogenesis analysis showed that ARCND- 
nMCS have defects in their ability to form bone. We observed 
significantly decreased levels and activity of ALP in nMSC- 
derived from affected family members resulting in a decrease in 
matrix mineralisation, which may suggest a delay in the process 
of mineralisation. Interestingly, this is in opposition to the find-
ings in nMSC of RCPS, which showed increased mineralisa-
tion.17 Even though reduced iNCC migration was observed in 
ARCND and RCPS, the underdeveloped mandible observed in 
patients with these disorders may depend on different molecular 
pathways. Notably, TWIST1 expression in ARCND- nMSC did 
not show significant differences during the osteogenic differen-
tiation as compared with control cells. Decreased ossification 
could potentially be related to the dynamics of TWIST1 dimeri-
sation at a previous stage of the cellular differentiation, as these 
cells were differentiated from iNCCs with higher TWIST1 levels 
in patients as compared with controls. Increased expression 
levels of TWIST1 in iNCCs would lead to an alteration in the 
ratios of TWIST1 homodimers and heterodimers (with E- pro-
teins such as TCF3, TCF4 and TCF12). Studies of cranial sutures 
suggest an antagonistic relationship with TWIST1 homodimers 
activating FGFR2 and osteogenic genes for ossification, while 
TWIST1 heterodimers, for example TWIST1- TCF3, promote 
mesenchymal expansion.80 89 We should also consider as an addi-
tional contributing factor to deregulated osteogenesis the role 
of TWIST1 in regulating osteogenesis by its direct interaction 
with RUNX2 in preosteoblasts.78 Interestingly, overexpression 
of Hand2, a partner of Twist1 in mandible differentiation and an 
inhibitor of Runx2, leads to delayed ossification, characterised 
by ALP low levels,90 which is comparable with our findings. We 
speculate that the reduced iNCC migration and the delayed ossi-
fication in nMSC differentiation could relate to altered expres-
sion of TWIST1 in early stages of NCC that would depend on 
the availability of the bHLH class partners or inhibitor of DNA- 
binding (ID) proteins.91 Further studies are necessary to test 
these hypotheses.
In summary, our data suggest that a unique 430 kb tandem 
duplication at the HDAC9/TWIST1 locus is pathogenic, causing 
deregulation of TWIST1 expression, which leads to the devel-
opment of ARCND features through compromised neural crest 
migration and osteogenic differentiation, thus representing a 
novel mechanism to be investigated in the aetiology of ARCND.
Author affiliations
1Genética e Biologia Evolutiva, Universidade de São Paulo Instituto de Biociências, 
Sao Paulo, Brazil
2Clinical Genetics Group, MRC Weatherall Institute of Molecular Medicine, John 
Radcliffe Hospital, University of Oxford, Oxford, UK
3Molecular Oncology Center, Hospital Sírio- Libanês, Sao Paulo, Brazil
9Romanelli Tavares VL, et al. J Med Genet 2021;0:1–11. doi:10.1136/jmedgenet-2021-107825
Novel disease loci
4Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
5Leiden Genome Technology Center, Leiden University Medical Center, Leiden, The 
Netherlands
6Centro de Atendimento Integral ao Fissurado Lábio Palatal, Curitiba, Brazil
Acknowledgements We are grateful to the family for their participation in 
this study. We thank Gabriela Hsia, Claudia Ismania, Naila Lourenço, Simone 
Ferreira, Tatiana T Torres, Guilherme L Yamamoto, Gerson Kobayashi, Silvia S Costa, 
Josiane Souza, Fabiana Poerner, Aimee Fenwick, Jim R Hughes, Simon MacGowan, 
Nils Koelling, Timothy Rostron, John Frankland and the Human Developmental 
Biology Resource. This study makes use of information generated by the DECIPHER 
community. A full list of centres that contributed to the generation of the data 
is available from https:// decipher. sanger. ac. uk/ about/ stats and via email from  
decipher@ sanger. ac. uk.
Contributors VLRT conducted Sanger sequencing, linkage analysis, whole exome 
sequencing analysis, gene prioritisation and CNV analysis. SLG- R performed in 
vitro cellular studies and real- time QPCR. YZ conducted targeted sequencing and 
Capture- C. CM performed linkage analysis. SE conducted whole exome sequencing 
analysis. DPM performed microsatellite experiment. HB conducted exome data 
processing. RSF identified patients, collected and analysed clinical data, and 
provided the biological specimens. JTDD conducted whole exome sequencing. SRFT 
conducted targeted sequencing and Capture- C. VLRT, SLG- R, SRFT and MRP- B wrote 
the manuscript. SRFT and MRP- B supervised and conceived the study. MRP- B is 
responsible for the overall content of the manuscript acting as guarantor. All the 
authors revised the manuscript for important intellectual content and approved the 
final version.
Funding Work was supported by CEPID/FAPESP (2013/08028- 1) and CNPq 
(MRPB/303712/2016- 3) in Brazil and in Oxford: Action Medical Research (GN2483 
to SRFT), VTCT Foundation Fellowship (SRFT, Andrew Wilkie), the MRC through 
the WIMM Strategic Alliance (G0902418 and MC_UU_12025) and Wellcome 
(Investigator Award 102731 to Andrew Wilkie and Project Grant 093329 to Andrew 
Wilkie and SRFT). Funding for the DECIPHER project was provided by Wellcome.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval Approval for this study was obtained from the Ethics 
Committee of the Instituto de Biociências - Universidade de São Paulo (CAAE: 
06216813.4.0000.5464).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the 
article or uploaded as supplementary information.
Supplemental material This content has been supplied by the author(s). It 
has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have 
been peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Vanessa Luiza Romanelli Tavares http:// orcid. org/ 0000- 0002- 8845- 5952
Stephen R F Twigg http:// orcid. org/ 0000- 0001- 5024- 049X
Maria Rita Passos- Bueno http:// orcid. org/ 0000- 0002- 9248- 3008
REFERENCES
 1 Kokitsu- Nakata NM, Zechi- Ceide RM, Vendramini- Pittoli S, Romanelli Tavares VL, 
Passos- Bueno MR, Guion- Almeida ML. Confronting a diagnostic challenge. Am J Med 
Genet Part A 2012;158 A:59–65.
 2 Gordon CT, Vuillot A, Marlin S, Gerkes E, Henderson A, AlKindy A, Holder- Espinasse 
M, Park SS, Omarjee A, Sanchis- Borja M, Bdira EB, Oufadem M, Sikkema- Raddatz 
B, Stewart A, Palmer R, McGowan R, Petit F, Delobel B, Speicher MR, Aurora P, 
Kilner D, Pellerin P, Simon M, Bonnefont J- P, Tobias ES, García- Miñaúr S, Bitner- 
Glindzicz M, Lindholm P, Meijer BA, Abadie V, Denoyelle F, Vazquez M- P, Rotky- Fast 
C, Couloigner V, Pierrot S, Manach Y, Breton S, Hendriks YMC, Munnich A, Jakobsen 
L, Kroisel P, Lin A, Kaban LB, Basel- Vanagaite L, Wilson L, Cunningham ML, Lyonnet 
S, Amiel J. Heterogeneity of mutational mechanisms and modes of inheritance in 
auriculocondylar syndrome. J Med Genet 2013;50:174–86.
 3 Papagrigorakis MJ, Karamolegou M, Vilos G, Apostolidis C, Karamesinis K, Synodinos 
PN. Auriculo- condylar syndrome. Angle Orthod 2012;82:556–64.
 4 Green SA, Simoes- Costa M, Bronner ME. Evolution of vertebrates as viewed from the 
crest. Nature 2015;520:474–82.
 5 Graham A, Begbie J, McGonnell I. Significance of the cranial neural crest. Dev Dyn 
2004;229:5–13.
 6 Clouthier DE, Passos- Bueno MR, Tavares ALP, Lyonnet S, Amiel J, Gordon CT. 
Understanding the basis of auriculocondylar syndrome: insights from human, 
mouse and zebrafish genetic studies. Am J Med Genet C Semin Med Genet 
2013;163C:306–17.
 7 Ruest L- B, Xiang X, Lim K- C, Levi G, Clouthier DE. Endothelin- A receptor- dependent 
and -independent signaling pathways in establishing mandibular identity. 
Development 2004;131:4413–23.
 8 Clouthier DE, Hosoda K, Richardson JA, Williams SC, Yanagisawa H, Kuwaki T, 
Kumada M, Hammer RE, Yanagisawa M. Cranial and cardiac neural crest defects in 
endothelin- A receptor- deficient mice. Development 1998;125:813–24.
 9 Rieder MJ, Green GE, Park SS, Stamper BD, Gordon CT, Johnson JM, Cunniff CM, 
Smith JD, Emery SB, Lyonnet S, Amiel J, Holder M, Heggie AA, Bamshad MJ, Nickerson 
DA, Cox TC, Hing AV, Horst JA, Cunningham ML. A human homeotic transformation 
resulting from mutations in PLCB4 and GNAI3 causes auriculocondylar syndrome. Am 
J Hum Genet 2012;90:907–14.
 10 Gordon CT, Petit F, Kroisel PM, Jakobsen L, Zechi- Ceide RM, Oufadem M, Bole- 
Feysot C, Pruvost S, Masson C, Tores F, Hieu T, Nitschké P, Lindholm P, Pellerin 
P, Guion- Almeida ML, Kokitsu- Nakata NM, Vendramini- Pittoli S, Munnich A, 
Lyonnet S, Holder- Espinasse M, Amiel J. Mutations in endothelin 1 cause recessive 
auriculocondylar syndrome and dominant isolated question- mark ears. Am J Hum 
Genet 2013;93:1118–25.
 11 Kido Y, Gordon CT, Sakazume S, Ben Bdira E, Dattani M, Wilson LC, Lyonnet S, 
Murakami N, Cunningham ML, Amiel J, Nagai T. Further characterization of atypical 
features in auriculocondylar syndrome caused by recessive PLCB4 mutations. Am J 
Med Genet A 2013;161A:2339–46.
 12 Romanelli Tavares VL, Gordon CT, Zechi- Ceide RM, Kokitsu- Nakata NM, Voisin N, 
Tan TY, Heggie AA, Vendramini- Pittoli S, Propst EJ, Papsin BC, Torres TT, Buermans H, 
Capelo LP, den Dunnen JT, Guion- Almeida ML, Lyonnet S, Amiel J, Passos- Bueno MR. 
Novel variants in GNAI3 associated with auriculocondylar syndrome strengthen a 
common dominant negative effect. Eur J Hum Genet 2015;23:481–5.
 13 Masotti C, Oliveira KG, Poerner F, Splendore A, Souza J, Freitas RdaS, Zechi- Ceide R, 
Guion- Almeida ML, Passos- Bueno MR. Auriculo- condylar syndrome: mapping of a first 
locus and evidence for genetic heterogeneity. Eur J Hum Genet 2008;16:145–52.
 14 Beverdam A, Merlo GR, Paleari L, Mantero S, Genova F, Barbieri O, Janvier P, Levi G. 
Jaw transformation with gain of symmetry after Dlx5/Dlx6 inactivation: mirror of the 
past? Genesis 2002;34:221–7.
 15 Depew MJ, Lufkin T, Rubenstein JLR. Specification of jaw subdivisions by Dlx genes. 
Science 2002;298:381–5.
 16 Rabadán- Diehl C, Nathanielsz P. From mice to men: research models of developmental 
programming. J Dev Orig Health Dis 2013;4:3–9.
 17 Miller EE, Kobayashi GS, Musso CM, Allen M, Ishiy FAA, de Caires LC, Goulart E, 
Griesi- Oliveira K, Zechi- Ceide RM, Richieri- Costa A, Bertola DR, Passos- Bueno 
MR, Silver DL. Eif4A3 deficient human iPSCs and mouse models demonstrate 
neural crest defects that underlie Richieri- Costa- Pereira syndrome. Hum Mol Genet 
2017;26:2177–91.
 18 Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev 2009;30:204–13.
 19 Kobayashi GS, Musso CM, Moreira DdeP, Pontillo- Guimarães G, Hsia GSP, Caires- 
Júnior LC, Goulart E, Passos- Bueno MR. Recapitulation of neural crest specification 
and EMT via induction from neural plate Border- like cells. Stem Cell Reports 
2020;15:776–88.
 20 Favaro FP, Alvizi L, Zechi- Ceide RM, Bertola D, Felix TM, de Souza J, Raskin S, Twigg 
SRF, Weiner AMJ, Armas P, Margarit E, Calcaterra NB, Andersen GR, McGowan SJ, 
Wilkie AOM, Richieri- Costa A, de Almeida MLG, Passos- Bueno MR. A noncoding 
expansion in eIF4A3 causes Richieri- Costa- Pereira syndrome, a craniofacial disorder 
associated with limb defects. Am J Hum Genet 2014;94:120–8.
 21 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA 
from human nucleated cells. Nucleic Acids Res 1988;16:1215.
 22 Romanelli Tavares VL, Zechi- Ceide RM, Bertola DR, Gordon CT, Ferreira SG, Hsia 
GSP, Yamamoto GL, Ezquina SAM, Kokitsu- Nakata NM, Vendramini- Pittoli S, Freitas 
RS, Souza J, Raposo- Amaral CA, Zatz M, Amiel J, Guion- Almeida ML, Passos- Bueno 
MR. Targeted molecular investigation in patients within the clinical spectrum of 
Auriculocondylar syndrome. Am J Med Genet A 2017;173:938–45.
 23 Hoffmann K, Lindner TH. easyLINKAGE- Plus--automated linkage analyses using large- 
scale SNP data. Bioinformatics 2005;21:3565–7.
 24 O’Connell JR, Weeks DE. PedCheck: a program for identification of genotype 
incompatibilities in linkage analysis. Am J Hum Genet 1998;63:259–66.
 25 Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin--rapid analysis of dense 
genetic maps using sparse gene flow trees. Nat Genet 2002;30:97–101.
 26 Kruglyak L, Daly MJ, Reeve- Daly MP, Lander ES. Parametric and nonparametric linkage 
analysis: a unified multipoint approach. Am J Hum Genet 1996;58:1347–63.
10 Romanelli Tavares VL, et al. J Med Genet 2021;0:1–11. doi:10.1136/jmedgenet-2021-107825
Novel disease loci
 27 Tranchevent L- C, Ardeshirdavani A, ElShal S, Alcaide D, Aerts J, Auboeuf D, Moreau Y. 
Candidate gene prioritization with endeavour. Nucleic Acids Res 2016;44:W117–21.
 28 Li H, Durbin R. Fast and accurate short read alignment with Burrows- Wheeler 
transform. Bioinformatics 2009;25:1754–60.
 29 McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella 
K, Altshuler D, Gabriel S, Daly M, DePristo MA. The genome analysis toolkit: a 
MapReduce framework for analyzing next- generation DNA sequencing data. Genome 
Res 2010;20:1297–303.
 30 Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants 
from high- throughput sequencing data. Nucleic Acids Res 2010;38:e164.
 31 Zhou Y, Koelling N, Fenwick AL, McGowan SJ, Calpena E, Wall SA, Smithson SF, Wilkie 
AOM, Twigg SRF. Disruption of Twist1 translation by 5’ UTR variants in Saethre- 
Chotzen syndrome. Hum Mutat 2018;39:1360–5.
 32 Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence 
data. Bioinformatics 2014;30:2114–20.
 33 Koelling N, Bernkopf M, Calpena E, Maher GJ, Miller KA, Ralph HK, Goriely A, 
Wilkie AOM. amplimap: a versatile tool to process and analyze targeted NGS data. 
Bioinformatics 2019;35:5349–50.
 34 Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic 
features. Bioinformatics 2010;26:841–2.
 35 Rimmer A, Phan H, Mathieson I, Iqbal Z, Twigg SRF, Wilkie AOM, McVean G, Lunter 
G, WGS500 Consortium. Integrating mapping-, assembly- and haplotype- based 
approaches for calling variants in clinical sequencing applications. Nat Genet 
2014;46:912–8.
 36 Davies JOJ, Telenius JM, McGowan SJ, Roberts NA, Taylor S, Higgs DR, Hughes JR. 
Multiplexed analysis of chromosome conformation at vastly improved sensitivity. Nat 
Methods 2016;13:74–80.
 37 Ishiy FAA, Fanganiello RD, Griesi- Oliveira K, Suzuki AM, Kobayashi GS, Morales AG, 
Capelo LP, Passos- Bueno MR. Improvement of in vitro osteogenic potential through 
differentiation of induced pluripotent stem cells from human exfoliated dental tissue 
towards mesenchymal- like stem cells. Stem Cells Int 2015;2015:1–9.
 38 Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A, Goshima N, 
Yamanaka S. An efficient nonviral method to generate integration- free human- 
induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells 
2013;31:458–66.
 39 Menendez L, Kulik MJ, Page AT, Park SS, Lauderdale JD, Cunningham ML, Dalton S. 
Directed differentiation of human pluripotent cells to neural crest stem cells. Nat 
Protoc 2013;8:203–12.
 40 Pfaffl MW. A new mathematical model for relative quantification in real- time RT- PCR. 
Nucleic Acids Res 2001;29:e45
 41 Ott J. Analysis of human genetic linkage. Maryland: The Johns Hopkins University 
Press, 1999.
 42 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier- Foster J, Grody WW, Hegde M, 
Lyon E, Spector E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance 
Committee. Standards and guidelines for the interpretation of sequence variants: a 
joint consensus recommendation of the American College of medical genetics and 
genomics and the association for molecular pathology. Genet Med 2015;17:405–23.
 43 Bildsoe H, Loebel DAF, Jones VJ, Chen Y- T, Behringer RR, Tam PPL. Requirement for 
Twist1 in frontonasal and skull vault development in the mouse embryo. Dev Biol 
2009;331:176–88.
 44 Bildsoe H, Loebel DAF, Jones VJ, Hor ACC, Braithwaite AW, Chen Y- T, Behringer RR, 
Tam PPL. The mesenchymal architecture of the cranial mesoderm of mouse embryos is 
disrupted by the loss of Twist1 function. Dev Biol 2013;374:295–307.
 45 Serrano MJ, So S, Svoboda KKH, Hinton RJ. Cell fate mediators Notch and twist in 
mouse mandibular condylar cartilage. Arch Oral Biol 2011;56:607–13.
 46 Zhang Y, Blackwell EL, McKnight MT, Knutsen GR, Vu WT, Ruest LB. Specific 
inactivation of Twist1 in the mandibular arch neural crest cells affects the 
development of the ramus and reveals interactions with Hand2. Dev Dyn 
2012;241:924–40.
 47 Petrie K, Guidez F, Howell L, Healy L, Waxman S, Greaves M, Zelent A. The 
histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem 
2003;278:16059–72.
 48 Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, Van Vooren S, 
Moreau Y, Pettett RM, Carter NP. Decipher: database of chromosomal imbalance and 
phenotype in humans using Ensembl resources. Am J Hum Genet 2009;84:524–33.
 49 Birnbaum RY, Clowney EJ, Agamy O, Kim MJ, Zhao J, Yamanaka T, Pappalardo Z, Clarke 
SL, Wenger AM, Nguyen L, Gurrieri F, Everman DB, Schwartz CE, Birk OS, Bejerano G, 
Lomvardas S, Ahituv N. Coding exons function as tissue- specific enhancers of nearby 
genes. Genome Res 2012;22:1059–68.
 50 Hughes JR, Roberts N, McGowan S, Hay D, Giannoulatou E, Lynch M, De Gobbi M, 
Taylor S, Gibbons R, Higgs DR. Analysis of hundreds of cis- regulatory landscapes at 
high resolution in a single, high- throughput experiment. Nat Genet 2014;46:205–12.
 51 Hirsch N, Eshel R, Bar Yaacov R, Shahar T, Shmulevich F, Dahan I, Levaot N, Kaplan T, 
Lupiáñez DG, Birnbaum RY, Nobrega MA. Unraveling the transcriptional regulation of 
Twist1 in limb development. PLoS Genet 2018;14:e1007738.
 52 Vieux- Rochas M, Mantero S, Heude E, Barbieri O, Astigiano S, Couly G, Kurihara H, 
Levi G, Merlo GR. Spatio- Temporal dynamics of gene expression of the Edn1- Dlx5/6 
pathway during development of the lower jaw. Genesis 2010;48:262–373.
 53 Miller CT, Yelon D, Stainier DYR, Kimmel CB. Two endothelin 1 effectors, HAND2 
and BAPX1, pattern ventral pharyngeal cartilage and the jaw joint. Development 
2003;130:1353–65.
 54 Clouthier DE, Williams SC, Yanagisawa H, Wieduwilt M, Richardson JA, Yanagisawa 
M. Signaling pathways crucial for craniofacial development revealed by endothelin- A 
receptor- deficient mice. Dev Biol 2000;217:10–24.
 55 Lehalle D, Wieczorek D, Zechi- Ceide RM, Passos- Bueno MR, Lyonnet S, Amiel J, 
Gordon CT. A review of craniofacial disorders caused by spliceosomal defects. Clin 
Genet 2015;88:405–15.
 56 Jones NC, Lynn ML, Gaudenz K, Sakai D, Aoto K, Rey J- P, Glynn EF, Ellington L, Du 
C, Dixon J, Dixon MJ, Trainor PA. Prevention of the neurocristopathy Treacher Collins 
syndrome through inhibition of p53 function. Nat Med 2008;14:125–33.
 57 Siekmann TE, Gerber MM, Toland AE. Variants in an HDAC9 intronic enhancer plasmid 
impact Twist1 expression in vitro. Mamm Genome 2016;27:99–110.
 58 Reardon W, McManus SP, Summers D, Winter RM. Cytogenetic evidence that the 
Saethre- Chotzen gene maps to 7p21.2. Am J Med Genet 1993;47:633–6.
 59 Wilkie AO, Yang SP, Summers D, Poole MD, Reardon W, Winter RM. Saethre- Chotzen 
syndrome associated with balanced translocations involving 7p21: three further 
families. J Med Genet 1995;32:174–80.
 60 Rose CS, Patel P, Reardon W, Malcolm S, Winter RM. The twist gene, although not 
disrupted in Saethre- Chotzen patients with apparently balanced translocations of 
7p21, is mutated in familial and sporadic cases. Hum Mol Genet 1997;6:1369–73.
 61 De Marco P, Raso A, Beri S, Gimelli S, Merello E, Mascelli S, Baldi M, Baffico AM, 
Pavanello M, Cama A, Capra V, Giorda R, Gimelli G. A de novo balanced translocation 
t(7;12)(p21.2;p12.3) in a patient with Saethre- Chotzen- like phenotype downregulates 
TWIST and an osteoclastic protein- tyrosine phosphatase, PTP- oc. Eur J Med Genet 
2011;54:e478–83.
 62 Visel A, Minovitsky S, Dubchak I, Pennacchio LA. VISTA Enhancer Browser--a database 
of tissue- specific human enhancers. Nucleic Acids Res 2007;35:D88–92.
 63 Ohdo S, Suzumori K, Madokoro H, Sonoda T, Hayakawa K. Partial trisomy for 7p due 
to maternal balanced translocation. Jinrui Idengaku Zasshi 1983;28:297–300.
 64 Stankiewicz P, Thiele H, Baldermann C, Krüger A, Giannakudis I, Dörr S, Werner N, 
Kunz J, Rappold GA, Hansmann I. Phenotypic findings due to trisomy 7p15.3- pter 
including the twist locus. Am J Med Genet 2001;103:56–62.
 65 S A, Padmalatha VO, G S, T D, T R, Kulashekaran KM, J M, N C, S L, Kandukuri LR. De 
novo 7p partial trisomy characterized by subtelomeric fish and whole- genome array in 
a girl with mental retardation. Mol Cytogenet 2011;4:1–10.
 66 Willner JP, Paciuc S, Criatian S, Hsu LYF, Murphy R, Hirschhorn K. The 7p partial trisomy 
syndrome. Pediatr Res 1977;11:530.
 67 Mégarbané A, Le Lorc’H M, Elghezal H, Joly G, Souraty N, Samaras L, Prieur M, 
Vekemans M, Turleau C, Romana SP. Pure partial 7p trisomy including the twist, 
HOXA, and Gli3 genes. J Med Genet 2001;38:178–82.
 68 Bukowska- Olech E, Sowińska- Seidler A, Łojek F, Popiel D, Walczak- Sztulpa J, Jamsheer 
A. Further phenotypic delineation of the auriculocondylar syndrome type 2 with 
literature review. J Appl Genet 2021;62:107–13.
 69 de Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP. Histone 
deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 
2003;370:737–49.
 70 Yang R, Wu Y, Wang M, Sun Z, Zou J, Zhang Y, Cui H. Hdac9 promotes glioblastoma 
growth via TAZ- mediated EGFR pathway activation. Oncotarget 2015;6:7644–56.
 71 Lapierre M, Linares A, Dalvai M, Duraffourd C, Bonnet S, Boulahtouf A, Rodriguez 
C, Jalaguier S, Assou S, Orsetti B, Balaguer P, Maudelonde T, Blache P, Bystricky 
K, Boulle N, Cavaillès V. Histone deacetylase 9 regulates breast cancer cell 
proliferation and the response to histone deacetylase inhibitors. Oncotarget 
2016;7:19693–708.
 72 Rastogi B, Raut SK, Panda NK, Rattan V, Radotra BD, Khullar M. Overexpression 
of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle 
progression, and inhibits apoptosis. Mol Cell Biochem 2016;415:183–96.
 73 Jin Z, Wei W, Huynh H, Wan Y. Hdac9 inhibits osteoclastogenesis via mutual 
suppression of PPARγ/RANKL signaling. Mol Endocrinol 2015;29:730–8.
 74 Ehnert S, Heuberger E, Linnemann C, Nussler A, Pscherer S. TGF-β1- Dependent 
downregulation of HDAC9 inhibits maturation of human osteoblasts. J Funct Morphol 
Kinesiol 2017;2.
 75 el Ghouzzi V, Le Merrer M, Perrin- Schmitt F, Lajeunie E, Benit P, Renier D, Bourgeois P, 
Bolcato- Bellemin AL, Munnich A, Bonaventure J. Mutations of the twist gene in the 
Saethre- Chotzen syndrome. Nat Genet 1997;15:42–6.
 76 Howard TD, Paznekas WA, Green ED, Chiang LC, Ma N, Ortiz de Luna RI, Garcia 
Delgado C, Gonzalez- Ramos M, Kline AD, Jabs EW. Mutations in twist, a basic 
helix- loop- helix transcription factor, in Saethre- Chotzen syndrome. Nat Genet 
1997;15:36–41.
 77 Kim S, Twigg SRF, Scanlon VA, Chandra A, Hansen TJ, Alsubait A, Fenwick AL, 
McGowan SJ, Lord H, Lester T, Sweeney E, Weber A, Cox H, Wilkie AOM, Golden A, 
Corsi AK. Localized Twist1 and Twist2 basic domain substitutions cause four distinct 
human diseases that can be modeled in Caenorhabditis elegans. Hum Mol Genet 
2017;26:2118–32.
 78 Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, Wu H, Yu K, Ornitz DM, 
Olson EN, Justice MJ, Karsenty G. A twist code determines the onset of osteoblast 
differentiation. Dev Cell 2004;6:423–35.
11Romanelli Tavares VL, et al. J Med Genet 2021;0:1–11. doi:10.1136/jmedgenet-2021-107825
Novel disease loci
 79 Hinoi E, Bialek P, Chen Y- T, Rached M- T, Groner Y, Behringer RR, Ornitz DM, Karsenty 
G. Runx2 inhibits chondrocyte proliferation and hypertrophy through its expression in 
the perichondrium. Genes Dev 2006;20:2937–42.
 80 Connerney J, Andreeva V, Leshem Y, Muentener C, Mercado MA, Spicer DB. 
Twist1 dimer selection regulates cranial suture patterning and fusion. Dev. Dyn. 
2006;235:1334–46.
 81 Lee MS, Lowe GN, Strong DD, Wergedal JE, Glackin CA. Twist, a basic helix- loop- 
helix transcription factor, can regulate the human osteogenic lineage. J Cell Biochem 
1999;75:566–77.
 82 Yanagisawa H, Clouthier DE, Richardson JA, Charité J, Olson EN. Targeted deletion 
of a branchial arch- specific enhancer reveals a role of dHAND in craniofacial 
development. Development 2003;130:1069–78.
 83 Firulli BA, Krawchuk D, Centonze VE, Vargesson N, Virshup DM, Conway SJ, Cserjesi 
P, Laufer E, Firulli AB. Altered Twist1 and HAND2 dimerization is associated with 
Saethre- Chotzen syndrome and limb abnormalities. Nat Genet 2005;37:373–81.
 84 Firulli BA, Redick BA, Conway SJ, Firulli AB. Mutations within helix I of Twist1 
result in distinct limb defects and variation of DNA binding affinities. J Biol Chem 
2007;282:27536–46.
 85 Chen ZF, Behringer RR. Twist is required in head mesenchyme for cranial neural tube 
morphogenesis. Genes Dev 1995;9:686–99.
 86 Soo K, O’Rourke MP, Khoo P- L, Steiner KA, Wong N, Behringer RR, Tam PPL. Twist 
function is required for the morphogenesis of the cephalic neural tube and the 
differentiation of the cranial neural crest cells in the mouse embryo. Dev Biol 
2002;247:251–70.
 87 Alexander C, Zuniga E, Blitz IL, Wada N, Le Pabic P, Javidan Y, Zhang T, Cho 
KW, Crump JG, Schilling TF. Combinatorial roles for BMPs and endothelin 1 in 
patterning the dorsal- ventral axis of the craniofacial skeleton. Development 
2011;138:5135–46.
 88 Huang M, Miller ML, McHenry LK, Zheng T, Zhen Q, Ilkhanizadeh S, Conklin BR, 
Bronner ME, Weiss WA. Generating trunk neural crest from human pluripotent stem 
cells. Sci Rep 2016;6:19727.
 89 Connerney J, Andreeva V, Leshem Y, Mercado MA, Dowell K, Yang X, Lindner V, Friesel 
RE, Spicer DB. Twist1 homodimers enhance FGF responsiveness of the cranial sutures 
and promote suture closure. Dev Biol 2008;318:323–34.
 90 Funato N, Chapman SL, McKee MD, Funato H, Morris JA, Shelton JM, Richardson 
JA, Yanagisawa H. Hand2 controls osteoblast differentiation in the branchial arch by 
inhibiting DNA binding of Runx2. Development 2009;136:615–25.
 91 Fan X, Waardenberg AJ, Demuth M, Osteil P, Sun JQJ, Loebel DAF, Graham M, Tam 
PPL, Fossat N. Twist1 homodimers and heterodimers orchestrate lineage- specific 
differentiation. Mol Cell Biol 2020;40:e00663- 19.
